Sudeep Pharma uploads Q4FY26 earnings call audio
Sudeep Pharma has uploaded the audio recording of its earnings call for Q4FY26, held on May 22, 2026, in compliance with Regulation 30 of the SEBI Listing Regulations, 2015. The recording is accessible via the company's official website, while the official transcript is set to be submitted separately to the exchanges.

*this image is generated using AI for illustrative purposes only.
Sudeep Pharma has uploaded the audio recording of its earnings call for the fourth quarter of the fiscal year 2026. The recording corresponds to the proceedings held on May 22, 2026, and is now available for access on the company’s official website.
The disclosure was made in reference to Regulation 30 of the SEBI Listing Regulations, 2015. The company had previously intimated the exchanges regarding the schedule for the earnings call and the investor presentation.
Accessing the Recording
Stakeholders and interested investors can listen to the audio recording directly through the link provided on the Sudeep Pharma website. The specific file, named for the quarter, has been hosted to ensure transparency and broad access to the financial discussions.
Key Details
| Event | Date | Status |
|---|---|---|
| Earnings Call Date | May 22, 2026 | Held |
| Audio Upload | May 22, 2026 | Available |
| Transcript Submission | Pending | To be submitted |
The company confirmed that while the audio is currently available, the official transcript of the earnings call will be submitted to the exchanges separately. This ensures that a written record of the management's commentary and financial analysis is also on the public record.
Historical Stock Returns for Sudeep Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.48% | +7.37% | +3.23% | -9.99% | -9.99% | -9.99% |
What key financial metrics and guidance did Sudeep Pharma's management reveal during the Q4 FY2026 earnings call that could signal future growth trajectory?
How does Sudeep Pharma's Q4 FY2026 performance compare to industry peers, and what does this imply for its competitive positioning in the pharmaceutical sector?
What strategic initiatives or pipeline developments did management discuss that could impact Sudeep Pharma's revenue outlook for FY2027?


































